Prestige BioPharma Balance Sheet

Financials in millions KRW. Fiscal year is July - June.

Millions KRW. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '24 Sep 30, 2024	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020
Cash & Equivalents	173,318	219,433	125,022	268,651	458,975	45,976
Short-Term Investments	52,442	9,381	176,390	25,584	-	2,423
Trading Asset Securities	-	-	-	9,035	377.68	-
Cash & Short-Term Investments	225,760	228,815	301,412	303,270	459,353	48,399
Cash Growth	-21.86%	-24.09%	-0.61%	-33.98%	849.10%	-
Receivables	390	391.6	132.72	-	-	-
Inventory	18,560	18,103	7,146	2,157	-	-
Prepaid Expenses	3,408	2,733	2,731	-	-	1,412
Other Current Assets	560.95	309.41	53.44	6,139	584.08	-
Total Current Assets	248,678	250,352	311,476	311,566	459,937	49,811
Property, Plant & Equipment	339,471	327,062	310,438	38,342	6,437	4,519
Long-Term Investments	-	-	-	74,710	24,159	9,049
Goodwill	10,244	10,785	10,192	-	-	-
Other Intangible Assets	30,003	31,327	29,877	4,288	450.33	386.92
Long-Term Deferred Charges	87,764	91,643	78,843	61,024	108,573	94,624
Other Long-Term Assets	493.33	551.5	775.14	9,883	4,611	1,709
Total Assets	716,654	711,720	741,600	499,813	604,166	160,098
Accounts Payable	436.72	2,282	462.15	2,624	-	-
Accrued Expenses	5,353	5,975	6,150	4,923	3,552	1,099
Short-Term Debt	19,794	15,439	31,188	-	2,873	-
Current Portion of Long-Term Debt	47,419	47,845	31,176	-	-	-
Current Portion of Leases	1,117	950.81	1,682	1,593	1,326	443.84
Current Unearned Revenue	-	-	-	-	565	231.5
Other Current Liabilities	102,406	73,366	64,231	32,654	5,730	6,702
Total Current Liabilities	176,526	145,857	134,888	41,794	14,046	8,477
Long-Term Debt	41,183	40,247	50,190	-	-	61.26
Long-Term Leases	1,092	624.04	1,326	2,656	3,571	2,373
Long-Term Unearned Revenue	-	-	-	25,427	11,588	11,387
Long-Term Deferred Tax Liabilities	7,357	7,755	7,368	-	-	-
Other Long-Term Liabilities	1,949	1,734	1,593	0	-	-
Total Liabilities	228,107	196,219	195,365	69,877	29,206	22,299
Common Stock	693,750	730,340	690,175	679,713	594,072	152,779
Additional Paid-In Capital	-30,911	7,865	7,286	7,175	-	-
Retained Earnings	-285,653	-294,797	-246,151	-259,601	-27,954	-21,891
Comprehensive Income & Other	1,154	-4,321	-798.76	2,649	8,843	6,911
Total Common Equity	378,340	439,087	450,511	429,936	574,961	137,799
Minority Interest	110,207	76,414	95,724	-	-	-
Shareholders' Equity	488,546	515,502	546,235	429,936	574,961	137,799
Total Liabilities & Equity	716,654	711,720	741,600	499,813	604,166	160,098
Total Debt	110,606	105,106	115,561	4,249	7,771	2,878
Net Cash (Debt)	115,154	123,708	185,851	299,020	451,582	45,521
Net Cash Growth	-43.23%	-33.44%	-37.85%	-33.78%	892.04%	-
Net Cash Per Share	1909.38	2058.50	3092.56	4975.70	8751.18	1067.23
Filing Date Shares Outstanding	60.87	300.48	300.48	300.48	300.48	44.71
Total Common Shares Outstanding	60.87	300.48	300.48	300.48	300.48	44.71
Working Capital	72,152	104,494	176,588	269,771	445,890	41,335
Book Value Per Share	6215.65	1461.28	1499.30	1430.83	1913.47	3082.31
Tangible Book Value	338,092	396,976	410,442	425,647	574,510	137,413
Tangible Book Value Per Share	5554.44	1321.13	1365.95	1416.55	1911.97	3073.66
Land	27,517	27,704	26,567	12,055	-	-
Buildings	77,296	77,472	76,415	-	-	-
Machinery	72,397	72,427	51,848	10,175	3,455	2,809
Construction In Progress	168,438	152,876	169,147	15,415	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.